The Virginia Biosciences Health Research Corporation (VBHRC), now known as Virginia Catalyst, today announced that it is accepting applications/letters of intent (LOIs) for round eight of grants to fund the development and commercialization of life science projects that address major unmet needs for improving human health. The awards, which range from $200,000 to $800,000, will accelerate translational research in the Commonwealth of Virginia through collaborations between industry and Virginia research universities. The purpose of this funding is to:

• Fund innovative, collaborative, translational research projects that elevate the level of sponsored research at Virginia’s universities and have the potential to significantly improve human health and create high value jobs in the Commonwealth
• Accelerate commercialization of our research university inventions and discoveries and to achieve competitive critical mass through robust collaborations of our research universities and industry

 
Letters of intent must be received by February 1, 2018 at 5:00 PM EST. Projects that meet criteria will be invited to submit a full application. Awards will be announced in April 2018. 

​Read the full press release here.

The Virginia Biosciences Health Research Corporation, known as Virginia Catalyst, today announced that it has awarded a $500,000 grant to a collaborative bioscience commercialization project including a team from Virginia Commonwealth University, Virginia Tech, Inova Health System and Indivior Inc., a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy. This grant, which includes matching funding of $500,000 provided by Indivior, is intended to catalyze the development and commercialization of life science projects that address major unmet needs for improving human health, while also contributing to Virginia’s economic growth. This project is focused on addressing neuroscience initiatives involving the treatment and care of patients recovering from an opioid overdose.

​Read the full press release.